HCPCS Code M1192

Patients with an existing diagnosis of squamous cell carcinoma of the esophagus
Code effective Jan 01, 2023

M1192 is a valid 2026 HCPCS code meaning Patients with an existing diagnosis of squamous cell carcinoma of the esophagus or (Pt w/ dx sq cell ca of esoph) for short. HCPCS M1192 has been effective since 01/01/2023 and applies to Medical care.

HCPCS Code Details - M1192
HCPCS Level II Code Section M - Medical services
HCPCS Code	`M1192`
Description	Long description: Patients with an existing diagnosis of squamous cell carcinoma of the esophagus Short description: Pt w/ dx sq cell ca of esoph
HCPCS Pricing indicator	`00` - Physician Fee Schedule And Non-Physician Practitioners - Service not separately priced by part B (e.g., services not covered, bundled, used by Part A only, etc.)
Multiple pricing indicator	`9` - Not applicable as HCPCS not priced separately by part B or value is not established
Coverage code	`C` - Carrier judgment
BETOS² code	`Z2` - Undefined codes
HCPCS Action code	`N` - No maintenance for this code
Type of service	`1` - Medical care
Effective date	Effective Jan 01, 2023
Date added	Added Jan 01, 2023

HCPCS M1191 · Hospice services provided to patient any time during the measurement period
HCPCS M1018 · Patients with an active diagnosis or history of cancer (except basal cell and squamous cell skin carcinoma), patients who are heavy tobacco smokers, lung cancer screening patients
HCPCS M1386 · Patients with an excisional surgery for melanoma or melanoma in situ in the past 5 years with an initial ajcc staging of 0, i, or ii at the start of the performance period
HCPCS M1447 · Patients with an active diagnosis of bipolar disorder any time prior to the end of the measure assessment period
HCPCS M1448 · Patients with an active diagnosis of personality disorder any time prior to the end of the measure assessment period
HCPCS M1449 · Patients with an active diagnosis of schizophrenia or psychotic disorder any time prior to the end of the measure assessment period
HCPCS M1451 · Patients with an active diagnosis of pervasive developmental disorder any time prior to the end of the measure assessment period
HCPCS M1467 · Patients with an existing diagnosis of lynch syndrome
HCPCS M1193 · Surgical pathology reports that contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both

¹ Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).

² BETOS stands for “Berenson-Eggers Type Of Service”

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026

HCPCS Code M1192

HCPCS Code Details - M1192

See also

HCPCS M1191 · Hospice services provided to patient any time during the measurement period

HCPCS M1018 · Patients with an active diagnosis or history of cancer (except basal cell and squamous cell skin carcinoma), patients who are heavy tobacco smokers, lung cancer screening patients

HCPCS M1386 · Patients with an excisional surgery for melanoma or melanoma in situ in the past 5 years with an initial ajcc staging of 0, i, or ii at the start of the performance period

HCPCS M1447 · Patients with an active diagnosis of bipolar disorder any time prior to the end of the measure assessment period

HCPCS M1448 · Patients with an active diagnosis of personality disorder any time prior to the end of the measure assessment period

HCPCS M1449 · Patients with an active diagnosis of schizophrenia or psychotic disorder any time prior to the end of the measure assessment period

HCPCS M1451 · Patients with an active diagnosis of pervasive developmental disorder any time prior to the end of the measure assessment period

HCPCS M1467 · Patients with an existing diagnosis of lynch syndrome

HCPCS M1193 · Surgical pathology reports that contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both